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Nijmegen, Netherlands
Antitumor immunity is shaped by the different types of immune cells that are present 
in the tumor microenvironment (TME). In particular, environmental signals (for instance, 
soluble factors or cell–cell contact) transmitted through the plasma membrane determine 
whether immune cells are activated or inhibited. Tetraspanin proteins are emerging as 
central building blocks of the plasma membrane by their capacity to cluster immune 
receptors, enzymes, and signaling molecules into the tetraspanin web. Whereas some 
tetraspanins (CD81, CD151, CD9) are widely and broadly expressed, others (CD53, 
CD37, Tssc6) have an expression pattern restricted to hematopoietic cells. Studies 
using genetic mouse models have identified important immunological functions of these 
tetraspanins on different leukocyte subsets, and as such, may be involved in the immune 
response against tumors. While multiple studies have been performed with regards to 
deciphering the function of tetraspanins on cancer cells, the effect of tetraspanins on 
immune cells in the antitumor response remains understudied. In this review, we will 
focus on tetraspanins expressed by immune cells and discuss their potential role in anti-
tumor immunity. New insights in tetraspanin function in the TME and possible prognostic 
and therapeutic roles of tetraspanins will be discussed.
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inTRODUCTiOn
It is now well known that the immune system plays an important role in preventing tumor formation, 
growth, and metastasis. This is exemplified by the increased susceptibility of immunocompromised 
patients to develop cancer, and by the recent success of novel cancer immunotherapies including 
checkpoint inhibitors, dendritic cell (DC) vaccination, and chimeric antigen receptor T cells, which 
demonstrate that the immune system can be harnessed against cancer.
Antitumor immunity is dependent on tumor cell uptake by antigen-presenting cells (APCs) 
(DCs, macrophages) that subsequently migrate to nearby lymph nodes to activate T and B cells. 
After clonal expansion, antigen-specific CD8 T cells can migrate toward the tumor, aiming to destroy 
tumor cells, a process called tumor immunosurveillance. However, this process is far from perfect as 
non-immunogenic variants of the tumor escape, resulting in tumor recurrence (1, 2). Escape from 
the immune system can also occur in other ways, for instance, by inducing an immunosuppressive 
state in the tumor microenvironment (TME) (3, 4). Here, tumors create a niche where they recruit 
different cell types to create a specific microenvironment, which favors tumor growth and metastasis 
(5). These cells include immune cells, which often have acquired immunosuppressive properties, 
such as regulatory T cells (Tregs), tumor-associated macrophages, and myeloid-derived suppressor 
cells (MDSCs) (6, 7) (Figure 1). Tumor-associated macrophages are very plastic cells that can adapt 
their phenotype in response to different tumor cell products or hypoxia (8). Alterations in cellular 
FigURe 1 | Tetraspanins on immune cells in the tumor microenvironment (TME). The TME is comprised of several different cells, including tumor cells and different 
immune infiltrating cells. Immune cells in the TME produce different soluble factors, including cytokines or antibodies. Each immune cell subset contains its own 
distinct tetraspanin web composed of tetraspanins that can have either stimulating or inhibitory functions (see Table 1). We hypothesize that immune cells alter the 
composition of the tetraspanin web when they migrate from the lymph node to the tumor caused by the immunesuppressive environment of tumors. Abbreviations: 
DC, dendritic cell; MDSC, myeloid-derived suppressor cell.
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phenotypes are often accompanied by membrane protein reor-
ganization, as different membrane receptors will be upregulated 
or internalized.
Tetraspanins, or transmembrane-four superfamily proteins, 
are evolutionary conserved membrane organizers that regulate 
protein trafficking, adhesion, migration, fusion, and signaling 
(9–12). While many tetraspanins (CD9, CD81, CD151) are widely 
expressed, others are restricted to hematopoietic cells (CD37, 
CD53, Tssc6). Tetraspanins are not constitutively expressed 
on all cell types and can differ between effector fates (13–15). 
Tetraspanins can interact with each other and with partner pro-
teins on the same cell whereby they form “tetraspanin-enriched 
microdomains” (TEMs) or “tetraspanin web” (9, 11, 16). The over-
all view is that tetraspanins are modulators of signal transduction, 
providing organization to membrane domains through lateral 
interaction with their partners (11, 17–23), including integrins 
[reviewed in Ref. (24)] and immunoreceptors [CD19 (25), MHC 
class molecules (17, 18)]. The immunological importance of these 
interactions has been demonstrated in multiple tetraspanin-
deficient (−/−) mice (CD37, CD53, CD81, CD82, Tssc6, CD151) 
that have defects in humoral and/or cellular immune responses 
(14, 26–29). These defects include cell migration, T cell prolif-
eration (27, 30–32), antibody production (25, 33), and antigen 
presentation (14, 34–36). As such, it is likely that they also control 
antitumor immunity. While studies have clearly demonstrated 
effects of tetraspanins in primary tumor progression [reviewed in 
Ref. (37)] or metastasis [reviewed in Ref. (38)], detailed analyses 
of antitumor immunity in tetraspanin −/− mice is still scarce.
Studies on human tumor cells reported associations between 
tetraspanin expression and tumor progression showing both 
reduced (CD82, CD9) and increased expression (CD151, 
Tspan8) in various cancer types (12, 15, 37–47). In patients with 
invasive breast cancer, it was shown that CD9 on immune cells 
was associated with a longer disease free survival, while CD9 
expression on the tumor cells showed the opposite effect (48). The 
relevance of CD37 in tumor suppression has been recently shown 
in CD37−/− mice that spontaneously develop B-cell lymphoma, 
and in patients with CD37-negative B-cell lymphoma that have 
poor survival (45, 49). These results are in line with studies that 
report tetraspanin expression to serve as a prognostic marker 
for cancer patients (50). In addition, these findings indicate that 
tetraspanins not only influence immune cell signaling but also 
directly protect from tumor formation. This review focuses on 
tetraspanins expressed on immune cells, and their possible role 
in antitumor responses and the TME.
TeTRASPAninS AnD AnTigen 
PReSenTATiOn
The first steps in an antitumor immune response are the uptake, 
processing, and presentation of tumor antigens by APCs. DCs 
are the most professional APCs, and infiltration of mature 
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activated DCs into tumors has been associated with increased 
patient survival. There is also ample evidence that tumors can 
inhibit APCs, leading to escape from antitumor responses (51). 
CD53, CD81, CD82, and CD37 have been shown to associate 
with MHC class II complexes (17, 52–54). Recently, CD9 was 
reported to be involved in MHC class II trafficking in human 
monocyte-derived DCs (35). The functional consequences 
of these interactions are demonstrated by altered antigen 
presentation capacity of tetraspanin−/− DCs. Both CD37−/− and 
CD151−/− DCs were hyperstimulatory to CD4 and CD8 T cells, 
although by different underlying mechanisms. CD151 was 
involved in inhibiting co-stimulation, while absence of CD37 led 
to increased peptide presentation (34). In Tccs6xCD37 double 
knock-out mice, an exaggerated hyperstimulatory phenotype of 
DCs was observed compared to DCs of single knock-out mice 
(55). This study indicates complementary functions for these 
two tetraspanins. In addition, DCs lacking CD82 had defects 
in processing MHC class II (14). Tetraspanin function in cross-
presentation (the presentation of extracellular antigens in the 
context of MHC class I) by DCs has not been investigated, but 
is not unlikely considering that CD53, CD81, and CD82 inter-
act with MHC class I molecules [(17), and own unpublished 
data]. Moreover, DCs lacking CD82 showed defective DC–T 
conjugate formation (14), and CD81 was found enriched in 
the contact area between APCs and T cells (56), supporting a 
function for tetraspanins in immunological synapse formation. 
Finally, tetraspanins (CD63, CD9, CD81, CD37) on exosomes 
may influence antigen presentation possibly via transfer of 
MHC–peptide complexes (57, 58). CD63 has been reported 
to inhibit antigen presentation as CD63 knockdown in APCs 
demonstrated increased secretion of exosomes containing 
MHCII (59). Together, these studies show that tetraspanins 
control antigen presentation either at the level of MHC–T cell 
receptor (TCR) interactions, at the level of co-stimulation, 
or via exosomes, which likely has implications for antitumor 
responses.
TeTRASPAninS AnD iMMUne CeLL 
MOTiLiTY
To mount an adequate immune response, immune cells need to 
migrate from peripheral tissues to draining lymph nodes and to 
the site of the tumor. It is well known that tetraspanins interact 
with multiple different integrins and as such influence the migra-
tory capacity of cells (60). In the immune system, absence of 
CD151 was found to decrease T cell motility, leading to reduced 
inflammation in a model for inflammatory bowel disease (61). 
Trafficking of DCs to lymph nodes has been studied in different 
tetraspanin-deficient mice. CD37−/− mice challenged with two 
different doses of an immunogenic tumor showed defective 
tumor rejection compared to wild-type (WT) mice, indicating 
that CD37 is directly involved in antitumor immunity (62). 
Using irradiated tumor cells, it was shown that T cell responses 
were impaired, which was due to impaired DC migration to 
the draining lymph nodes (62). A different study confirmed 
the decreased motility of CD37−/− DCs (14) and neutrophils 
(63), and increased motility of CD82−/− DCs (14). Interestingly, 
the functional effects of CD82 are opposite to those of CD37 
indicating that these tetraspanins counteract each other (14). 
Furthermore, CD81 was reported to be important in DC migra-
tion and formation of membrane protrusions in vitro (64). The 
underlying molecular mechanism involved cytoskeleton rear-
rangements via regulation of Rac-1 and RhoA, small GTPases 
that regulate the actin network. CD81 was required for Rac-1 
activation (65), CD82 negatively regulated RhoA, and CD37 
promoted activation of Rac-1 (27). Moreover, CD37, CD81, and 
CD82 have all been reported to interact with integrins (24, 33, 
52, 63, 66), and although leukocytes are not dependent on inte-
grins for migration in 3D environments (67), this may provide 
an additional mechanism for tetraspanin involvement in 2D 
migration. These studies show that tetraspanins are important 
in immune cell migration, thus making it likely they are also 
involved in leukocyte migration into the TME.
T AnD B CeLL ACTivATiOn AnD 
PROLiFeRATiOn
Activation of T cells depends on antigen recognition presented 
in MHC–peptide complexes on the surface of APCs during 
immunological synapse formation. Recently, it was determined 
that CD9 and CD151 support integrin-mediated signaling at the 
immunological synapse in T  cells (68). Accordingly, CD81 in 
T  cells was involved in the organization of the immunological 
synapse by interacting with ICAM-1 and CD3 (69).
Antigen-presenting cell–T  cell interaction and subsequent 
engagement of TCR and co-stimulatory molecules leads to 
naive T  cell activation and proliferation (70), which can occur 
in the nearby lymph nodes or the TME. It is well-known that 
tumor-infiltrating lymphocytes can be an important prognostic 
factor for cancer (71). More specifically, CD8 cytotoxic T cells are 
associated with favorable patient outcome while Tregs are associ-
ated with decreased survival (6, 72). Furthermore, the positive 
effect of immune checkpoint inhibitors on clinical outcome of 
patients with melanoma or lung carcinoma shows that exhausted/
dysfunctional T cells in the TME may be reactivated by anti-PD-1 
therapy (73, 74). Taken together, these studies underline the 
importance of T cells in anti-tumor immunity.
Different tetraspanins have been linked to T  cell prolif-
eration, as CD37−/−, CD151−/−, Tssc6−/−, and CD8−/− T  cells 
were all hyperproliferative upon TCR stimulation (27, 30–32). 
Moreover, double CD37−/− Tssc6−/− mice displayed an exagger-
ated hyperproliferative T cell response, and impaired formation 
of antigen-specific CD8+ T cells after infection (55). In contrast, 
CD151-positive human T cells exhibited increased proliferation 
compared to CD151-negative T cells (13).
Another important facet of T  cell biology is differentiation 
into different sub-types. CD81−/− mice displayed impaired Th2 
responses, possibly linking tetraspanins to T cell differentiation 
(32, 75–77). These mice fail to develop Th2-dependent allergic 
airway hyperreactivity (77). In vitro studies revealed that altered 
B–T  cell interactions were responsible for the deficient Th2 
response (76). These studies should be further expanded to 
investigate different T cell subsets, Th1-Th2 balance, and espe-
cially T cells in the TME (such as Tregs or Th17 cells) to unravel 
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tetraspanin function in T  cell differentiation during antitumor 
immunity.
A recent study with CD81−/− mice elegantly demonstrated 
that tumor growth and metastasis were severely impaired in 
CD81−/− mice compared to WT mice. Both Tregs and MDSCs 
lacking CD81 were observed to be deficient in their suppressive 
ability (46). This is one of the first studies investigating the effect 
of tetraspanins on regulatory immune cells.
B cells have a dual role in tumor immunity as they can both 
inhibit and stimulate tumor growth. Tumor-specific antibod-
ies produced by B  cells can opsonize tumor cells and lead to 
antibody-dependent cytotoxicity by natural killer (NK) cells 
and phagocytes. On the other hand, regulatory B cells (Bregs) 
secrete IL-10 and TGFβ, which directly inhibit effector immune 
cells, thus suppressing antitumor immunity (78). Tetraspanins 
function in humoral immunity has been evidenced by different 
studies in tetraspanin-deficient mice and the first documentation 
of a CD81-deficient patient. CD81 is important in the trafficking 
of CD19, part of the co-receptor complex of the B cell receptor 
(BCR), to the surface of B cells (25). BCR signaling occurs when 
B cells encounter their antigen and is important for B cell pro-
liferation, survival, and antibody production. Absence of CD81 
led to CD19-deficiency resulting in antibody defects in mice 
(32, 76) and humans (25). CD81−/− mice show impaired B cell 
proliferation, decreased responses to Th2 stimuli, decreased 
antibody production (32), and impaired B cell proliferation after 
BCR activation (26). CD53, although not required for CD19 
expression, is also important for B cell function, as we recently 
discovered that CD53 promoted BCR-dependent protein kinase 
C (PKC) signaling (19). Both human and murine CD53−/− B cells 
have defects in translocation of PKC to the plasma membrane, 
consistent with an elegant study demonstrating that CD82 
stabilizes PKC activation at the surface of leukemia cells (60). 
These findings indicate that tetraspanins can directly influence 
immune cell signaling. CD37 is highly expressed by B cells (79) 
and controls antibody production as shown in CD37−/− mice 
that display decreased IgG and increased IgA levels, which is a 
B-cell intrinsic phenotype (29, 80). The underlying mechanism 
involved CD37 regulation of α4β1 integrin-Akt signaling, which 
is required during follicular DC–B  cell interactions and supports 
survival of IgG1-secreting cells (33). The importance of CD37 
in B cell survival has been confirmed in an independent study 
demonstrating that the cytoplasmic domains of CD37 couple to 
the Pi3K–Akt survival pathway (81). Tetraspanin function in 
anti-tumor immunity is further supported by our unpublished 
findings showing increased tumor growth in CD53−/− mice 
compared to WT mice using a syngeneic immunogenic tumor 
model (F. Schaper et al., in preparation), which is in accordance 
with the impaired anti-tumor immunity observed in CD37−/− 
mice (62).
To conclude, tetraspanins have crucial functions in both T and 
B cell proliferation, survival, and signaling. It is interesting that 
these functions are non-redundant (deficiency of one tetraspanin 
results in a certain phenotype) and specific (for example CD81 
controls CD19, whereas CD37 controls α4β1 integrin on B cells). 
Given these specific functions of tetraspanins and their partner 
molecules, it stands to reason that this can result in either an 
antitumor or pro-tumor response mediated by immune cells in 
the TME.
CYTOKine PRODUCTiOn AnD OTHeR 
eFFeCTOR FUnCTiOnS
Cytokines are a central part of cellular communication and 
stimulate cell migration to sides of inflammation. These cytokines 
can be either immunosuppressive (IL-10, TGFβ, or IL-35) or 
proinflammatory (IL-12, γIFN, TNFα). Several studies dem-
onstrated that tetraspanins can influence cytokine production. 
CD37 has been reported to inhibit IL-6 signaling upon infection 
(80, 82, 83), and during lymphomageneses (45). CD53 has been 
implicated as negative regulator of IL-6, TNFα, and IL-1β in a 
population study of house dust mite (84) and linked to TNF-α by 
genome-wide association studies (85). In line with this, CD81−/− 
DCs produced more TNF-α compared to WT DCs upon Listeria 
infection (86). Additionally, TNF-α production was increased by 
CD9−/− macrophages compared to WT macrophages after stimu-
lation with LPS (87). CD9 has also been linked to production 
of TGFβ and IL-10. Bregs are known to produce large amounts 
of IL-10 and two independent mouse studies discovered that 
CD9 could serve as novel phenotypic marker for Bregs (88, 89). 
Although CD9−/− mice do not have aberrant B cell development 
or humoral immunity (90), Breg presence and function in CD9−/− 
mice has not been investigated to date.
In a small study of patients with metastatic melanoma, CD9 
expression on NK cells was observed to correlate strongly with 
serum levels of TGFβ (91). Interestingly, CD9 was absent on 
NK  cells in healthy controls, but upregulated after incubation 
with TGFβ (91, 92). These CD9-positive NK cells are normally 
found in the maternal part of the placenta (93), where they exert 
immunosuppressive actions. These data indicate that suppressive 
factors, which are also found in the TME, can alter tetraspa-
nin expression on immune cells, which has immunological 
consequences.
FUTURe DiReCTiveS: TeTRASPAninS On 
iMMUne CeLLS in THe TMe
Tetraspanins are emerging as important organizing proteins on 
immune cells that control both humoral and cellular immune 
responses (Table 1), by either stimulating or inhibiting immune 
cell function. However, more insight is needed into understand-
ing tetraspanins on immune cells in the TME including regula-
tory lymphocytes, MDSCs, and tumor-associated macrophages. 
Recently, CD81 has been demonstrated to control MDSC and 
Treg function in a murine tumor model, which is the first 
in vivo evidence of tetraspanin function in antitumor immunity 
(46). This, together with the finding that CD37−/− mice have 
impaired antitumor responses (62) indicates that tetraspanins 
directly contribute to antitumor immunity. However, tetras-
panin expression has thus far only been studied on immune 
cells from blood or bone marrow (79), and not yet in the TME. 
In this TME, both stimulating and suppressive immune cells 
are present, each with their own distinct tetraspanin web. We 
TABLe 1 | Key functions of individual tetraspanins on immune cell subsets.
Tetraspanin Function on immune cells
CD37 − T cell proliferation, peptide MHC presentation, antibody 
production, IL-6 signaling by B cells
+ Dendritic cell (DC) migration, B cell survival
CD53 + B cell receptor-dependent protein kinase C signaling
− IL-6, TNFα production
Tssc6 − T cell proliferation
CD9 − TNF-α production
+ MHC class II trafficking
CD81 − T cell proliferation, TNF-α production
+ DC motility, immunological synapse organization,  
Th2 response, antibody production
CD82 − DC migration
+ DC–T cell conjugation
+ Antigen presentation
CD151 − T cell proliferation, T cell motility, co-stimulation in DCs
CD63 − exosome secretion
−, inhibits; +, stimulates.
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propose a model in which tumor cells have the ability to alter 
the composition of the tetraspanin web on immune cells that 
enter the TME from the circulation (Figure  1). Tumor envi-
ronmental factors that may influence tetraspanin expression on 
immune cells include suppressive cytokines, low oxygen levels 
(hypoxia), growth factors, damage-associated molecular pat-
terns (DAMPs) and tumor-immune cell contact. These tumor 
environmental factors may either increase or decrease the 
expression of different tetraspanins on immune cells. Plasticity 
of immune cells plays an important role in the TME, and it is well 
established that immune cells can change their phenotype by 
altering membrane protein expression. Since altered (increased 
or decreased) tetraspanin expression affects immune cell func-
tion, we hypothesize that a changed tetraspanin web supports 
immune cell plasticity through altered membrane protein 
organization. This model is supported by (1) multiple studies 
demonstrating that tetraspanin-deficiency affects proliferation, 
migration, cytokine production, and antigen presentation, (2) 
CD9 upregulation on NK cells after TGFβ incubation leading 
to immunosuppressive NK  cells (91), (3) regulation of TGFβ 
by tetraspanins (94, 95), and (4) own unpublished observations 
demonstrating that human lymphocytes cultured with tumor 
cells change expression of multiple tetraspanins. We are only 
at the beginning of understanding the dynamic nature of the 
tetraspanin web on immune cells, and we envisage that its com-
position will change depending on the tumor state (elimination, 
equilibrium, or escape). Using multispectral imaging (79, 96) on 
resected tumor material from patients, effects on tetraspanin 
expression can be investigated in the future. We anticipate that 
targeting tetraspanins on specific immune subsets (such as CD9 
on Bregs) in the TME may have therapeutic potential. Hereby, 
it should be taken into account that the same tetraspanin can 
stimulate or inhibit immune cell function, depending on the 
immune cell type it is expressed on. Research investigating 
tetraspanins as therapeutic targets in cancer is already ongoing 
(50), exemplified by targeting CD37 in clinical trials for B cell 
malignancies (97, 98).
Taken together, further investigation into tetraspanin func-
tion on immune cells will add to our understanding of the role 
that these membrane proteins play in antitumor immunity and 
the possibility to target the tetraspanin web on immune cells in 
the TME.
AUTHOR COnTRiBUTiOnS
AS supervised the study and FS and AS both wrote the manuscript.
ACKnOwLeDgMenTS
AS is supported by the Netherlands Organization for Scientific 
Research Grant (NWO-ALW VIDI Grant 864.11.006), a Dutch 
Cancer Society Grant (KUN2014-6845), and the European 
Research Council (Consolidator Grant, 724281). We thank 
Dr. S. van Deventer, J. Weiden, and Dr. J. Land for critically read-
ing the manuscript. We apologize to all authors whose work could 
not be cited due to space limitations.
ReFeRenCeS
1. Schreiber RD. Cancer immunoediting: integrating suppression and promo-
tion. Science (2014) 331:1565–71. doi:10.1126/science.1203486 
2. Finn OJ. A believer’s overview of cancer immunosurveillance and immuno-
therapy. J Immunol (2018) 200:385–91. doi:10.4049/jimmunol.1701302 
3. Quail D, Joyce J. Microenvironmental regulation of tumor progression and 
metastasis. Nat Med (2013) 19:1423–37. doi:10.1038/nm.3394 
4. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. 
Immunity (2013) 39:61–73. doi:10.1016/j.immuni.2013.07.005 
5. Hanahan D, Coussens LM. Accessories to the crime: functions of cells 
recruited to the tumor microenvironment. Cancer Cell (2012) 21:309–22. 
doi:10.1016/j.ccr.2012.02.022 
6. van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM. 
Migrating into the tumor: a roadmap for T  cells. Trends Cancer (2017) 
3:797–808. doi:10.1016/j.trecan.2017.09.006 
7. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppres-
sive tumour network: myeloid-derived suppressor cells, regulatory T cells and 
natural killer T cells. Immunology (2013) 138:105–15. doi:10.1111/imm.12036 
8. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. 
J Clin Invest (2012) 122:787–95. doi:10.1172/JCI59643 
9. Charrin S, Jouannet S, Boucheix C, Rubinstein E. Tetraspanins at a glance. 
J Cell Sci (2014) 127:3641–8. doi:10.1242/jcs.154906 
10. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev 
Mol Cell Biol (2005) 6:801–11. doi:10.1038/nrm1736 
11. van Deventer SJ, Dunlock V-ME, van Spriel AB. Molecular interactions sha-
ping the tetraspanin web. Biochem Soc Trans (2017) 45:741–50. doi:10.1042/
BST20160284 
12. Beckwith KA, Byrd JC, Muthusamy N. Tetraspanins as therapeutic targets 
in hematological malignancy: a concise review. Front Physiol (2015) 6:91. 
doi:10.3389/fphys.2015.00091 
13. Seu L, Tidwell C, Timares L, Duverger A, Wagner FH, Goepfert PA, et  al. 
CD151 expression is associated with a hyperproliferative T cell phenotype. 
J Immunol (2017) 199:3336–47. doi:10.4049/jimmunol.1700648 
14. Jones EL, Wee JL, Demaria MC, Blakeley J, Ho PK, Vega-Ramos J, et  al. 
Dendritic cell migration and antigen presentation are coordinated by the 
opposing functions of the tetraspanins CD82 and CD37. J Immunol (2016) 
196:978–87. doi:10.4049/jimmunol.1500357 
6Schaper and van Spriel Tetraspanins in Anti-Tumor Immunity 
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1185
15. Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M, 
et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymph-
oproliferative disorders and its correlation with normal B-cell maturation. 
Leukemia (2005) 19:1376–83. doi:10.1038/sj.leu.2403822 
16. Zuidscherwoude M, Göttfert F, Dunlock VME, Figdor CG, van den Bogaart G, 
van Spriel AB. The tetraspanin web revisited by super-resolution microscopy. 
Sci Rep (2015) 5:12201. doi:10.1038/srep12201 
17. Engering A, Pieters J. Association of distinct tetraspanins with MHC class 
II molecules at different subcellular locations in human immature dendritic 
cells. Int Immunol (2001) 13:127–34. doi:10.1093/intimm/13.2.127 
18. Szöllósi J, Horejsí V, Bene L, Angelisová P, Damjanovich S. Supramolecular 
complexes of MHC class I, MHC class II, CD20, and tetraspan molecules 
(CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol (1996) 
157:2939–46. 
19. Zuidscherwoude M, Dunlock V-ME, van den Bogaart G, van Deventer SJ, 
van der Schaaf A, van Oostrum J, et al. Tetraspanin microdomains control 
localized protein kinase C signaling in B cells. Sci Signal (2017) 10:eaag2755. 
doi:10.1126/scisignal.aag2755 
20. Yunta M, Lazo PA. Apoptosis protection and survival signal by the 
CD53 tetraspanin antigen. Oncogene (2003) 22:1219–24. doi:10.1038/
sj.onc.1206183 
21. Levy S, Shoham T. The tetraspanin web modulates immune-signalling com-
plexes. Nat Rev Immunol (2005) 5:136–48. doi:10.1038/nri1548 
22. Termini CM, Gillette JM. Tetraspanins function as regulators of cellular 
signaling. Front Cell Dev Biol (2017) 5:34. doi:10.3389/fcell.2017.00034 
23. Yanez-Mo M, Barreiro O, Gordon-Alonso M, Sala-Valdes M, Sanchez-
Madrid F. Tetraspanin-enriched microdomains: a functional unit in cell 
plasma membranes. Trends Cell Biol (2009) 19:434–46. doi:10.1016/j.
tcb.2009.06.004 
24. Berditchevski F. Complexes of tetraspanins with integrins: more than meets 
the eye. J Cell Sci (2001) 114:4143–51. 
25. van Zelm MC, Smet J, Adams B, Mascart F, Schandené L, Janssen F, et al. 
CD81 gene defect in humans disrupts CD19 complex formation and leads 
to antibody deficiency. J Clin Invest (2010) 120:1265–74. doi:10.1172/
JCI39748 
26. Miyazaki T. Normal development but differentially altered proliferative 
responses of lymphocytes in mice lacking CD81. EMBO J (1997) 16:4217–25. 
doi:10.1093/emboj/16.14.4217 
27. Wright MD, Geary SM, Fitter S, Moseley GW, Lau L-M, Sheng K-C, et al. 
Characterization of mice lacking the tetraspanin superfamily member 
CD151. Mol Cell Biol (2004) 24:5978–88. doi:10.1128/MCB.24.13.5978- 
5988.2004 
28. Robb L, Tarrant J, Groom J, Ibrahim M, Li R, Borobakas B, et al. Molecular 
characterisation of mouse and human TSSC6: evidence that TSSC6 is a gen-
uine member of the tetraspanin superfamily and is expressed specifically in 
haematopoietic organs. Biochim Biophys Acta (2001) 1522:31–41. doi:10.1016/
S0167-4781(01)00306-2 
29. Knobeloch KP, Wright MD, Ochsenbein AF, Liesenfeld O, Lohler J, 
Zinkernagel RM, et  al. Targeted inactivation of the tetraspanin CD37 
impairs T-cell-dependent B-cell response under suboptimal costimulatory 
conditions. Mol Cell Biol (2000) 20:5363–9. doi:10.1128/MCB.20.15.5363- 
5369.2000 
30. van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z, et al.  
A regulatory role for CD37 in T  cell proliferation. J Immunol (2004) 
172:2953–61. doi:10.4049/jimmunol.172.5.2953 
31. Tarrant JM, Groom J, Metcalf D, Li R, Borobokas B, Wright MD, et al. The 
absence of Tssc6, a member of the tetraspanin superfamily, does not affect 
lymphoid development but enhances in vitro T-cell proliferative responses. 
Mol Cell Biol (2002) 22:5006–18. doi:10.1128/MCB.22.14.5006-5018.2002 
32. Maecker HT, Levy S. Normal lymphocyte development but delayed humoral 
immune response in CD81-null mice. J Exp Med (1997) 185:1505–10. 
doi:10.1084/jem.185.8.1505 
33. van Spriel AB, de Keijzer S, van der Schaaf A, Gartlan KH, Sofi M, Light A, 
et al. The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling 
axis and supports long-lived plasma cell survival. Sci Signal (2012) 5:ra82. 
doi:10.1126/scisignal.2003113 
34. Sheng K-C, van Spriel AB, Gartlan KH, Sofi M, Apostolopoulos V, Ashman L, 
et al. Tetraspanins CD37 and CD151 differentially regulate Ag presentation 
and T-cell co-stimulation by DC. Eur J Immunol (2009) 39:50–5. doi:10.1002/
eji.200838798 
35. Rocha-Perugini V, Martinez Del Hoyo G, Gonzalez-Granado JM, Ramirez-
Huesca M, Zorita V, Rubinstein E, et al. CD9 regulates major histocompatibil-
ity complex class II trafficking in monocyte-derived dendritic cells. Mol Cell 
Biol (2017) 37: e00202–17. doi:10.1128/MCB.00202-17 
36. Segura E, Villadangos JA. A modular and combinatorial view of the antigen 
cross-presentation pathway in dendritic cells. Traffic (2011) 12:1677–85. 
doi:10.1111/j.1600-0854.2011.01254.x 
37. Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nat Rev 
Cancer (2013) 14:49–60. doi:10.1038/nrc3640 
38. Zöller M. Tetraspanins: push and pull in suppressing and promoting meta-
stasis. Nat Rev Cancer (2009) 9:40–55. doi:10.1038/nrc2543 
39. Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, et al. Diminished 
metastasis in tetraspanin CD151-knockout mice. Blood (2012) 118:464–72. 
doi:10.1182/blood-2010-08-302240 
40. Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, 
et  al. Interrogation of functional cell-surface markers identifies CD151 
dependency in high-grade serous ovarian cancer. Cell Rep (2017) 18:2343–58. 
doi:10.1016/j.celrep.2017.02.028 
41. Romanska HM, Berditchevski F. Tetraspanins in human epithelial malignan-
cies. J Pathol (2011) 223:4–14. doi:10.1002/path.2779 
42. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 
(2006) 240:183–94. doi:10.1016/j.canlet.2005.08.018 
43. Vences-Catalan F, Duault C, Kuo C-C, Rajapaksa R, Levy R, Levy S. 
CD81 as a tumor target. Biochem Soc Trans (2017) 45:531–5. doi:10.1042/
BST20160478 
44. Di Giacomo V, Tian TV, Mas A, Pecoraro M, Batlle-Morera L, Noya L, et al. 
DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the 
bone through regulation of CD82. Oncogene (2017) 36:4381–92. doi:10.1038/
onc.2017.42 
45. De Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, 
et al. Tetraspanin CD37 protects against the development of B cell lymphoma. 
J Clin Invest (2016) 126:653–66. doi:10.1172/JCI81041 
46. Vences-Catalán F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, 
et  al. Tetraspanin CD81 promotes tumor growth and metastasis by modula ting 
the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res 
(2015) 75:4517–26. doi:10.1158/0008-5472.CAN-15-1021 
47. Veenbergen S, van Spriel AB. Tetraspanins in the immune response 
against cancer. Immunol Lett (2011) 138:129–36. doi:10.1016/j.imlet.2011. 
03.010 
48. Kwon HJ, Choi JE, Kang SH, Son Y, Bae YK. Prognostic significance of 
CD9 expression differs between tumour cells and stromal immune cells, 
and depends on the molecular subtype of the invasive breast carcinoma. 
Histopathology (2017) 70:1155–65. doi:10.1111/his.13184 
49. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, et al. 
Assessment of CD37 B-cell antigen and cell of origin significantly improves 
risk prediction in diffuse large B-cell lymphoma. Blood (2016) 128:3083–100. 
doi:10.1182/blood-2016-05-715094 
50. Hemler ME. Targeting of tetraspanin proteins – potential benefits and strate-
gies. Nat Rev Drug Discov (2008) 7:747–58. doi:10.1038/nrd2659 
51. Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer micro-
environment. J Cancer (2013) 4:36–44. doi:10.7150/jca.5046 
52. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, 
Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface 
tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 
(1996) 26:2657–65. doi:10.1002/eji.1830261117 
53. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The 
tetraspan protein CD82 is a resident of MHC class II compartments where 
it associates with HLA-DR, -DM, and -DO molecules. J Immunol (1998) 
161:3282–91. 
54. Angelisova P, Hilgert I, Horejsi V. Association of four antigens of the tetraspans 
family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. 
Immunogenetics (1994) 39:249–56. doi:10.1007/BF00188787 
55. Gartlan KH, Belz GT, Tarrant JM, Minigo G, Katsara M, Sheng K-C, 
et al. A complementary role for the tetraspanins CD37 and Tssc6 in cel-
lular immunity. J Immunol (2010) 185:3158–66. doi:10.4049/jimmunol. 
0902867 
7Schaper and van Spriel Tetraspanins in Anti-Tumor Immunity 
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1185
56. Mittelbrunn M, Yanez-Mo M, Sancho D, Ursa A, Sanchez-Madrid F. Cutting 
edge: dynamic redistribution of tetraspanin CD81 at the central zone of 
the immune synapse in both T  lymphocytes and APC. J Immunol (2002) 
169:6691–5. doi:10.4049/jimmunol.169.12.6691 
57. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, 
Sánchez-Cabo F, González MÁ, et  al. Unidirectional transfer of microRNA- 
loaded exosomes from T cells to antigen-presenting cells. Nat Commun (2011) 
2:282. doi:10.1038/ncomms1285 
58. Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and 
function. Front Immunol (2014) 5:442. doi:10.3389/fimmu.2014.00442 
59. Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F. 
The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur 
J Immunol (2011) 41:2556–61. doi:10.1002/eji.201141438 
60. Jiang X, Zhang J, Huang Y. Tetraspanins in cell migration. Cell Adh Migr 
(2015) 9:406–15. doi:10.1080/19336918.2015.1005465 
61. Zelman-Toister E, Bakos E, Cohen S, Zigmond E, Shezen E, Grabovsky V, et al. 
CD151 regulates T-cell migration in health and inflammatory bowel disease. 
Inflamm Bowel Dis (2016) 22:257–67. doi:10.1097/MIB.0000000000000621 
62. Gartlan KH, Wee JL, Demaria MC, Nastovska R, Chang TM, Jones EL, 
et  al. Tetraspanin CD37 contributes to the initiation of cellular immunity 
by promoting dendritic cell migration. Eur J Immunol (2013) 43:1208–19. 
doi:10.1002/eji.201242730 
63. Wee JL, Schulze KE, Jones EL, Yeung L, Cheng Q, Pereira CF, et al. Tetraspanin 
CD37 regulates β2 integrin-mediated adhesion and migration in neutrophils. 
J Immunol (2015) 195:5770–9. doi:10.4049/jimmunol.1402414 
64. Quast T, Eppler F, Semmling V, Schild C, Homsi Y, Levy S, et al. CD81 is essen-
tial for the formation of membrane protrusions and regulates Rac1-activation 
in adhesion-dependent immune cell migration. Blood (2011) 118:1818–27. 
doi:10.1182/blood-2010-12-326595 
65. Tejera E, Rocha-Perugini V, Lopez-Martin S, Perez-Hernandez D, Bachir AI, 
Horwitz AR, et al. CD81 regulates cell migration through its association 
with Rac GTPase. Mol Biol Cell (2013) 24:261–73. doi:10.1091/mbc.
E12-09-0642 
66. Todros-Dawda I, Kveberg L, Vaage JT, Inngjerdingen M. The tetraspanin 
CD53 modulates responses from activating NK  cell receptors, promoting 
LFA-1 activation and dampening NK cell effector functions. PLoS One (2014) 
9:e97844. doi:10.1371/journal.pone.0097844 
67. Lammermann T, Bader BL, Monkley SJ, Worbs T, Wedlich-Soldner R, Hirsch K, 
et al. Rapid leukocyte migration by integrin-independent flowing and squeez-
ing. Nature (2008) 453:51–5. doi:10.1038/nature06887 
68. Rocha-Perugini V, Gonzalez-Granado JM, Tejera E, Lopez-Martin S, 
Yanez-Mo M, Sanchez-Madrid F. Tetraspanins CD9 and CD151 at the immune 
synapse support T-cell integrin signaling. Eur J Immunol (2014) 44:1967–75. 
doi:10.1002/eji.201344235 
69. Rocha-Perugini V, Zamai M, Gonzalez-Granado JM, Barreiro O, Tejera E, 
Yanez-Mo M, et al. CD81 controls sustained T cell activation signaling and 
defines the maturation stages of cognate immunological synapses. Mol Cell 
Biol (2013) 33:3644–58. doi:10.1128/MCB.00302-13 
70. Chen L, Flies DB. Molecular mechanisms of T  cell co-stimulation and co- 
inhibition. Nat Rev Immunol (2013) 13:227–42. doi:10.1038/nri3405 
71. Pages F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautes-Fridman C, Fridman W-H. 
Immune infiltration in human tumors: a prognostic factor that should not be 
ignored. Oncogene (2010) 29:1093–102. doi:10.1038/onc.2009.416 
72. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The 
immune score as a new possible approach for the classification of cancer. 
J Transl Med (2012) 10:1. doi:10.1186/1479-5876-10-1 
73. Sharma P, Allison JP. The future of immune checkpoint therapy. Science (2015) 
348:56–61. doi:10.1126/science.aaa8172 
74. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. 
Nat Rev Cancer (2012) 12:252–64. doi:10.1038/nrc3239 
75. Levy S. Function of the tetraspanin molecule CD81 in B and T cells. Immunol 
Res (2014) 58:179–85. doi:10.1007/s12026-014-8490-7 
76. Deng J, Dekruyff RH, Freeman GJ, Umetsu DT, Levy S. Critical role of CD81 
in cognate T–B cell interactions leading to Th2 responses. Int Immunol (2002) 
14:513–23. doi:10.1093/intimm/14.5.513 
77. Deng J, Yeung VP, Tsitoura D, DeKruyff RH, Umetsu DT, Levy S. Allergen-
induced airway hyperreactivity is diminished in CD81-deficient mice. 
J Immunol (2000) 165:5054–61. doi:10.4049/jimmunol.165.9.5054 
78. Yuen GJ, Demissie E, Pillai S. B lymphocytes and cancer: a love-hate relation-
ship. Trends Cancer (2016) 2:747–57. doi:10.1016/j.trecan.2016.10.010 
79. de Winde CM, Zuidscherwoude M, Vasaturo A, van der Schaaf A, Figdor CG, 
van Spriel AB. Multispectral imaging reveals the tissue distribution of tetra-
spanins in human lymphoid organs. Histochem Cell Biol (2015) 144:133–46. 
doi:10.1007/s00418-015-1326-2 
80. van Spriel AB, Sofi M, Gartlan KH, van der Schaaf A, Verschueren I, 
Torensma R, et  al. The tetraspanin protein CD37 regulates IgA responses 
and anti-fungal immunity. PLoS Pathog (2009) 5:e1000338. doi:10.1371/
journal.ppat.1000338 
81. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, et  al. 
Tetraspanin CD37 directly mediates transduction of survival and apoptotic 
signals. Cancer Cell (2012) 21:694–708. doi:10.1016/j.ccr.2012.03.040 
82. Meyer-Wentrup F, Figdor CG, Ansems M, Brossart P, Wright MD, Adema GJ, 
et al. Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. 
J Immunol (2007) 178:154–62. doi:10.4049/jimmunol.178.1.154 
83. Yan J, Wu B, Huang B, Huang S, Jiang S, Lu F. Dectin-1-CD37 association 
regulates IL-6 expression during Toxoplasma gondii infection. Parasitol Res 
(2014) 113:2851–60. doi:10.1007/s00436-014-3946-1 
84. Lee H, Bae S, Jang J, Choi BW, Park CS, Park JS, et al. CD53, a suppressor of 
inflammatory cytokine production, is associated with population asthma risk 
via the functional promoter polymorphism -1560 C>T. Biochim Biophys Acta 
(2013) 1830:3011–8. doi:10.1016/j.bbagen.2012.12.030 
85. Bos SD, Lakenberg N, van der Breggen R, Houwing-Duistermaat JJ, 
Kloppenburg M, de Craen AJ, et al. A genome-wide linkage scan reveals CD53 
as an important regulator of innate TNF-α levels. Eur J Hum Genet (2010) 
18:953–9. doi:10.1038/ejhg.2010.52 
86. Martínez del Hoyo G, Ramírez-Huesca M, Levy S, Boucheix C, Rubinstein E, 
Minguito de la Escalera M, et al. CD81 controls immunity to Listeria infection 
through Rac-dependent inhibition of proinflammatory mediator release and 
activation of cytotoxic T cells. J Immunol (2015) 194:6090–101. doi:10.4049/
jimmunol.1402957 
87. Suzuki M, Tachibana I, Takeda Y, He P, Minami S, Iwasaki T, et al. Tetraspanin 
CD9 negatively regulates lipopolysaccharide-induced macrophage activation 
and lung inflammation. J Immunol (2009) 182:6485–93. doi:10.4049/jimmunol. 
0802797 
88. Sun J, Wang J, Pefanis E, Chao J, Rothschild G, Tachibana I, et al. Transcriptomics 
identify CD9 as a marker of murine IL-10-competent regulatory B cells. Cell 
Rep (2015) 13:1110–7. doi:10.1016/j.celrep.2015.09.070 
89. Matsushita T, Le Huu D, Kobayashi T, Hamaguchi Y, Hasegawa M, Naka K, 
et  al. A novel splenic B1 regulatory cell subset suppresses allergic disease 
through phosphatidylinositol 3-kinase–Akt pathway activation. J Allergy Clin 
Immunol (2016) 138:1170–82.e9. doi:10.1016/j.jaci.2015.12.1319 
90. Cariappa A, Shoham T, Liu H, Levy S, Boucheix C, Pillai S. The CD9 tetrasp-
anin is not required for the development of peripheral B cells or for humoral 
immunity. J Immunol (2005) 175:2925–30. doi:10.4049/jimmunol.175.5.2925 
91. Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN. 
Expansion of CD16-negative natural killer cells in the peripheral blood of 
patients with metastatic melanoma. Clin Dev Immunol (2011) 2011:316314. 
doi:10.1155/2011/316314 
92. Keskin DB, Allan DSJ, Rybalov B, Andzelm MM, Stern JNH, Kopcow HD, 
et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into 
CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A  
(2007) 104:3378–83. doi:10.1073/pnas.0611098104 
93. Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, 
et  al. Human decidual natural killer cells are a unique NK cell subset with 
immunomodulatory Potential. J Exp Med (2003) 198:1201–12. doi:10.1084/
jem.20030305 
94. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, 
et  al. Tetraspanin CD151 regulates transforming growth factor beta sig-
naling: implication in tumor metastasis. Cancer Res (2010) 70:6059–70. 
doi:10.1158/0008-5472.CAN-09-3497 
95. Wang H-X, Hemler ME. Novel impact of EWI-2, CD9, and CD81 on TGF-β 
signaling in melanoma. Mol Cell Oncol (2015) 2:e1030536. doi:10.1080/2372
3556.2015.1030536 
96. Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, 
Verweij D, et  al. Eight-color multiplex immunohistochemistry for simulta-
neous detection of multiple immune checkpoint molecules within the tumor 
8Schaper and van Spriel Tetraspanins in Anti-Tumor Immunity 
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1185
microenvironment. J Immunol (2018) 200:347–54. doi:10.4049/jimmunol. 
1701262 
97. Betrian S, Ysebaert L, Heider KH, Delord JP, Fournié JJ, Quillet-Mary A. 
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo- 
resistant/relapse-initiating CLL cells: a rationale for combination treatment. 
Blood Cancer J (2016) 6:e496–496. doi:10.1038/bcj.2016.106 
98. Hicks SW, Lai KC, Gavrilescu LC, Yi Y, Sikka S, Shah P, et al. The antitumor 
activity of IMGN529, a CD37-targeting antibody-drug conjugate, is poten-
tiated by rituximab in non-hodgkin lymphoma models. Neoplasia (2017) 
19:661–71. doi:10.1016/j.neo.2017.06.001 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Schaper and van Spriel. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) and the copyright owner are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, distribu-
tion or reproduction is permitted which does not comply with these terms.
